A Phase 2 interventional study of Placebo and M2951 in Rheumatoid Arthritis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-17.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 487th largest by enrollment of the 771 interventional ones that give a count, is one of 58 that started in 2016, is one of 215 in phase 2, and was the 654th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 58 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 802 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
Merck KGaA, Darmstadt, Germany has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: M2951
Drug: M2951
Drug: M2951
Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
Also known as: Evobrutinib
Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
Also known as: Evobrutinib
Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response
ACR 20 response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Proportion of ACR20 responders = Number of participants with ACR20 response divided by total participants.
Time frame: Day 84
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28
Mean change in the hsCRP concentration from baseline at Day 28 was reported.
Time frame: Baseline, Day 28
Proportion of Participants Achieving American College of Rheumatology-50 (ACR50) Response
ACR 50 response: \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR50 responders = Number of participants with ACR50 response divided by total participants.
Time frame: Day 28, Day 56 and Day 84
Proportion of Participants Achieving American College of Rheumatology-70 (ACR70) Response
ACR 70 response: \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR70 responders = Number of participants with ACR70 response divided by total participants.
Time frame: Day 28, Day 56 and Day 84
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84
Mean change in the hsCRP concentration from baseline at Day 84 was reported.
Time frame: Baseline, Day 84
Mean Change From Baseline in Disease Activity Score Based on a 28 Joint Count High-Sensitivity C-Reactive Protein (DAS28-hsCRP) at Day 28 and 84
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Baseline, Day 28 and Day 84
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2
DAS28-hsCRP consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt(TJC28) + 0.28\*sqrt(SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<3.2 were reported.
Time frame: Day 84
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6
DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt (TJC28) + 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<2.6 were reported.
Time frame: Day 84
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 28 and 84
Erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Higher values indicate inflammation in the body.
Time frame: Baseline, Day 28 and Day 84
Change From Baseline in Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody Levels at Day 28 and 84
Anti-cyclic citrullinated peptide (anti-CCP) is an antibody present in most rheumatoid arthritis participants.
Time frame: Baseline, Day 28 and Day 84
Change From Baseline in Rheumatoid Factor (RF) at Day 28 and 84
Rheumatoid Factor is an anti-body present in the blood.
Time frame: Baseline, Day 28 and Day 84
Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
Time frame: Baseline, Day 84
Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
Time frame: Baseline, Day 84
Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84
The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Day 84
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
Time frame: Baseline, Day 84
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to 16 Weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity
Grade 3 and 4 TEAES as per National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03) were presented. Grade 3 refers to severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care and Activity of daily living (ADL).Grade 4 refers to Life-threatening consequences; where urgent intervention indicated.
Time frame: Baseline up to 16 Weeks
Number of Participants With Grade 3 or Higher Clinically Significant Abnormality for Hematology, Biochemistry, Urinalysis or Coagulation
Clinically significant abnormalities for hematology, biochemistry or coagulation were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 toxicity grades, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death. Participants with grade 3 or higher were reported.
Time frame: Baseline up to 16 Weeks
Number of Participants With Clinically Significant Vital Signs Abnormalities
Vital sign assessment included blood pressure, pulse rate, respiratory rate and temperature. Clinical significance was determined by the investigator.
Time frame: Baseline up to 16 Weeks
Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings
The 12-lead ECG recordings were obtained after 10 minutes of rest in a semi-supine position. The ECG parameters obtained directly from the computerized 12-lead ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was determined by the investigator.
Time frame: Baseline up to 16 Weeks
Plasma Concentration of M2951
Time frame: Pre-dose at Day 1; 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Area Under the Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6h) of M2951
Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Maximum Observed Plasma Concentration (Cmax) of M2951
Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951
Time frame: Pre-dose on Day 29
Time to Reach Maximum Plasma Concentration (Tmax) of M2951
Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951
Accumulation ratio for AUC was calculated as AUC 0-6h, Day 29 divided by AUC 0-6h, Day 1
Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951
Accumulation ratio for Cmax , was calculated as Cmax, Day 29 divided by Cmax, Day1
Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Absolute Immunoglobulin Levels at Day 85
Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.
Time frame: Baseline, Day 85
Absolute Change From Baseline in Immunoglobulin Levels at Day 85
Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.
Time frame: Baseline, Day 85
Absolute B-Cell Levels at Day 85
Time frame: Day 85
Absolute Change From Baseline in B-cell Levels at Day 85
Time frame: Baseline, Day 85
| Milestone | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Placebo/M2951: Open-Label Extension Period | M2951/M2951: Open-Label Extension Period |
|---|---|---|---|---|
| Started | 32 | 33 | 0 | 0 |
| Completed | 24 | 27 | 0 | 0 |
| Not completed | 8 | 6 | 0 | 0 |
| Withdrew: Adverse event | 3 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Milestone | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Placebo/M2951: Open-Label Extension Period | M2951/M2951: Open-Label Extension Period |
|---|---|---|---|---|
| Started | 0 | 0 | 18 | 21 |
| Completed | 0 | 0 | 15 | 19 |
| Not completed | 0 | 0 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 |
ACR 20 response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Proportion of ACR20 responders = Number of participants with ACR20 response divided by total participants.
| proportion of participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response | 0.42 | 0.52 |
Mean change in the hsCRP concentration from baseline at Day 28 was reported.
| milligram/milliliter (mg/mL) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28 | -0.80 ± 2.00 | -2.72 ± 1.93 |
ACR 50 response: \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR50 responders = Number of participants with ACR50 response divided by total participants.
| proportion of participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Day 28 | 0.10 | 0.06 |
| Day 56 | 0.23 | 0.18 |
| Day 84 | 0.23 | 0.21 |
ACR 70 response: \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR70 responders = Number of participants with ACR70 response divided by total participants.
| proportion of participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Day 28 | 0.00 | 0.06 |
| Day 56 | 0.03 | 0.06 |
| Day 84 | 0.13 | 0.09 |
Mean change in the hsCRP concentration from baseline at Day 84 was reported.
| mg/mL | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84 | -2.14 ± 2.20 | -3.54 ± 2.13 |
Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| units on a scale | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change at Day 28 | -0.79 ± 0.14 | -0.87 ± 0.13 |
| Change at Day 84 | -1.35 ± 0.20 | -1.28 ± 0.19 |
DAS28-hsCRP consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt(TJC28) + 0.28\*sqrt(SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<3.2 were reported.
| proportion of participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2 | 0.13 | 0.21 |
DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt (TJC28) + 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<2.6 were reported.
| proportion of participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6 | 0.10 | 0.06 |
Erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Higher values indicate inflammation in the body.
| millimeter/hour (mm/hour) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change at Day 28 | -3 ± 36.9 | -7 ± 22.1 |
| Change at Day 84 | -3 ± 21.0 | -9 ± 21.1 |
Anti-cyclic citrullinated peptide (anti-CCP) is an antibody present in most rheumatoid arthritis participants.
| units/milliliter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change at Day 28 | 168 ± 991.1 | -138 ± 720.9 |
| Change at Day 84 | 301 ± 1282.6 | -396 ± 736.8 |
Rheumatoid Factor is an anti-body present in the blood.
| kiloUnit/Liter (kU/L) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change at Day 28 | -30 ± 124.2 | -7 ± 59.7 |
| Change at Day 84 | -34 ± 132.1 | -26 ± 79.9 |
The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).
| millimeter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84 | -21 ± 23.5 | -24 ± 24.6 |
The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.
| millimeter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84 | -19 ± 21.8 | -22 ± 22.0 |
The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84 | -0.3 ± 0.44 | -0.3 ± 0.41 |
The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).
| millimeter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84 | -33 ± 20.3 | -30 ± 22.7 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| TEAEs | 16 | 22 |
| SAEs | 0 | 1 |
Grade 3 and 4 TEAES as per National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03) were presented. Grade 3 refers to severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care and Activity of daily living (ADL).Grade 4 refers to Life-threatening consequences; where urgent intervention indicated.
| Participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| NCI-CTCAE Severity grade >=3 | 2 | 3 |
| NCI-CTCAE Severity grade >=4 | 0 | 1 |
Clinically significant abnormalities for hematology, biochemistry or coagulation were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 toxicity grades, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death. Participants with grade 3 or higher were reported.
| Participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Hematology | 2 | 0 |
| Biochemistry | 4 | 2 |
| Coagulation | 0 | 0 |
| Urinalysis | 0 | 0 |
Vital sign assessment included blood pressure, pulse rate, respiratory rate and temperature. Clinical significance was determined by the investigator.
| Participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 |
The 12-lead ECG recordings were obtained after 10 minutes of rest in a semi-supine position. The ECG parameters obtained directly from the computerized 12-lead ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was determined by the investigator.
| Participants | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings | 0 | 0 |
| nanogram per milliliter (ng/mL) | M2951: Double-Blind Treatment Period |
|---|---|
| Day 1: Pre-Dose: | 0.00 ± NA |
| Day 1: 0.25 hours post-dose | 10.3 ± 23.37 |
| Day 1: 0.5 hours post-dose | 80.5 ± 136.9 |
| Day 1: 1 hour post-dose | 160 ± 219.7 |
| Day 1: 2 hours post-dose | 125 ± 111.9 |
| Day 1: 4 hours post-dose | 47.3 ± 41.62 |
| Day 1: 6 hours post-dose | 23.7 ± 20.92 |
| Day 29: 0.25 hours post-dose | 22.0 ± 71.57 |
| Day 29: 0.5 hours post-dose | 88.4 ± 114.1 |
| Day 29: 1 hour post-dose | 120 ± 107.2 |
| Day 29: 2 hours post-dose | 82.3 ± 53.82 |
| Day 29: 4 hours post-dose | 62.1 ± 82.39 |
| Day 29: 6 hour post-dose | 37.2 ± 43.96 |
| hours*nanogram/milliliter | M2951: Double-Blind Treatment Period |
|---|---|
| Day 1 | 431 ± 390.9 |
| Day 29 | 414 ± 268.4 |
| ng/mL | M2951: Double-Blind Treatment Period |
|---|---|
| Day 1 | 206 ± 214.7 |
| Day 29 | 171 ± 130.1 |
| ng/mL | M2951: Double-Blind Treatment Period |
|---|---|
| Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951 | 5.47 ± 4.735 |
| hour | M2951: Double-Blind Treatment Period |
|---|---|
| Day 1 | 1.00 (0.50 to 4.00) |
| Day 29 | 1.00 (0.50 to 6.00) |
Accumulation ratio for AUC was calculated as AUC 0-6h, Day 29 divided by AUC 0-6h, Day 1
| ratio | M2951: Double-Blind Treatment Period |
|---|---|
| Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951 | 1.38 ± 1.134 |
Accumulation ratio for Cmax , was calculated as Cmax, Day 29 divided by Cmax, Day1
| ratio | M2951: Double-Blind Treatment Period |
|---|---|
| Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951 | 1.52 ± 1.929 |
Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.
| gram/Liter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Immunoglobulin A | 2.09 ± 0.968 | 2.77 ± 1.323 |
| Immunoglobulin G | 10.61 ± 3.897 | 9.88 ± 2.498 |
| Immunoglobulin G Subclass 1 | 6.20 ± 2.338 | 5.41 ± 1.574 |
| Immunoglobulin G Subclass 2 | 3.59 ± 1.644 | 3.74 ± 1.205 |
| Immunoglobulin G Subclass 3 | 1.05 ± 0.551 | 0.93 ± 0.510 |
| Immunoglobulin G Subclass 4 | 0.394 ± 0.2474 | 0.684 ± 0.6286 |
| Immunoglobulin M | 1.16 ± 0.365 | 1.16 ± 0.642 |
Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.
| gram/Liter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Immunoglobulin A | -0.07 ± 0.263 | -0.04 ± 0.133 |
| Immunoglobulin G | 0.02 ± 1.281 | -0.30 ± 0.517 |
| Immunoglobulin G Subclass 1 | 0.11 ± 0.857 | -0.15 ± 0.410 |
| Immunoglobulin G Subclass 2 | -0.13 ± 0.477 | -0.17 ± 0.404 |
| Immunoglobulin G Subclass 3 | 0.07 ± 0.214 | -0.04 ± 0.209 |
| Immunoglobulin G Subclass 4 | -0.028 ± 0.1073 | -0.046 ± 0.2576 |
| Immunoglobulin M | -0.04 ± 0.177 | -0.25 ± 0.255 |
| cells per micro-liter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Absolute B-Cell Levels at Day 85 | 243 ± 265.0 | 204 ± 154.0 |
| cells per micro-liter | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period |
|---|---|---|
| Absolute Change From Baseline in B-cell Levels at Day 85 | 76 ± 242.0 | 11 ± 73.2 |
Collected over Double-Blind Period: Baseline up to 16 weeks; Open-Label Period: Baseline up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Double-Blind Treatment Period | 0/32 (0%) | 0/32 (0%) | 13/32 (40.6%) |
| M2951: Double-Blind Treatment Period | 0/33 (0%) | 1/33 (3%) | 17/33 (51.5%) |
| Placebo/M2951: Open-Label Extension Period | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| M2951/M2951: Open-Label Extension Period | 0/21 (0%) | 0/21 (0%) | 10/21 (47.6%) |
| Event | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Placebo/M2951: Open-Label Extension Period | M2951/M2951: Open-Label Extension Period |
|---|---|---|---|---|
| Vestibular disorderEar and labyrinth disorders | 0/32 | 1/33 | 0/18 | 0/21 |
| Vertigo CNS originNervous system disorders | 0/32 | 1/33 | 0/18 | 0/21 |
| Event | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Placebo/M2951: Open-Label Extension Period | M2951/M2951: Open-Label Extension Period |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/32 | 0/33 | 0/18 | 3/21 |
| Viral upper respiratory tract infectionInfections and infestations | 4/32 | 3/33 | 1/18 | 0/21 |
| Alanine aminotransferase increasedInvestigations | 4/32 | 1/33 | 1/18 | 0/21 |
| Amylase increasedInvestigations | 3/32 | 1/33 | 2/18 | 0/21 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/32 | 0/33 | 2/18 | 1/21 |
| NauseaGastrointestinal disorders | 3/32 | 3/33 | 0/18 | 2/21 |
| VomitingGastrointestinal disorders | 1/32 | 2/33 | 0/18 | 2/21 |
| Respiratory tract infectionInfections and infestations | 0/32 | 2/33 | 0/18 | 2/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/32 | 2/33 | 0/18 | 2/21 |
| HeadacheNervous system disorders | 0/32 | 2/33 | 0/18 | 2/21 |
The Safety Analysis Set included all participants who received at least 1 dose of M2951 or placebo.
| Age, Continuous(years) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Total |
|---|---|---|---|
| Mean | 53.1 ± 12.19 | 53.8 ± 10.73 | 53.4 ± 11.39 |
| Sex: Female, Male(Participants) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Total |
|---|---|---|---|
| Female | 25 | 24 | 49 |
| Male | 7 | 9 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 31 | 32 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo: Double-Blind Treatment Period | M2951: Double-Blind Treatment Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 2 |
| White | 31 | 31 | 62 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Apr 2017, 8 months.
Results were first posted in May 2018, 1 year 1 month after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 8 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
EMD Serono Research & Development Institute, Inc. →